Home › Calculator › XGN Dividend Calculator 2026
XGN Dividend DRIP Calculator 2026
25.71% YieldHealthcareExagen Inc. · NASDAQ
Price: $7.78 · Annual div: $2.00/share · Frequency: quarterly · Payout ratio: 50% · Ex-div: TBD
Calculator settings
Portfolio growth: DRIP vs No DRIP
Annual dividend income growth
💡 What-if scenarios
Click to apply scenario to the calculator
🎯 When XGN pays your bills
Year your monthly dividend income covers each expense (based on current settings)
Share your XGN snowball 📈
$10,000 in XGN → $128.7K in 10 years · $3,693.18/month
About Exagen Inc. (XGN) — Dividend Analysis 2026
Exagen Inc. develops and commercializes diagnostic testing solutions, leveraging its proprietary cell-bound complement activation products (CB-CAPs) technology under the AVISE brand throughout the United States. The company's mission is to equip rheumatologists with advanced tools for the precise diagnosis, prognosis, and ongoing management of autoimmune and related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its flagship product, AVISE CTD, aids in distinguishing between various connective tissue diseases (CTDs) and other conditions with overlapping symptoms in symptomatic patients. The company's product portfolio includes AVISE Lupus, which assesses complement system activation by measuring B-cell C4d and erythrocyte-bound C4d in blood. AVISE APS offers a comprehensive panel of autoantibody tests for the diagnosis and management of Antiphospholipid Syndrome (APS). For SLE patients, AVISE SLE Prognostic provides an autoantibody panel to evaluate the potential for kidney, brain, and cardiovascular complications. Additionally, AVISE Vasculitis AAV utilizes a testing panel of individual analytes to assist physicians in the assessment and monitoring of anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis, while AVISE Anti-CarP helps identify RA patients prone to severe disease, and AVISE PC4d measures platelet-bound C4d. Further offerings include AVISE SLE Monitor, a biomarker blood test; AVISE MTX, a patented and validated blood test; and AVISE HCQ, designed to monitor hydroxychloroquine levels. Exagen also holds a research collaboration and license agreement with Allegheny Health Network (AHN) Research Institute to advance the development of novel patented biomarkers. Incorporated in 2002, the company was formerly known as Exagen Diagnostics, Inc. before rebranding to Exagen Inc. in January 2019. Its headquarters are located in Vista, California.
Compare XGN with similar stocks
This calculation uses the DividendFlow Engine v6.0. Data is verified daily against SEC filings and FMP real-time feeds to ensure projection accuracy.
Get Your Full XGN DRIP Report by Email
We'll send you a full breakdown of your projections, DRIP tips, and how to enable dividend reinvestment with your broker.
Free forever. No spam. Unsubscribe anytime. · Privacy Policy
Ready to invest? Open XGN position with:
🌍 XGN Yield by Country & Account Type
Real after-tax yield depends on where you live and how you hold XGN.
| Account/Country | Tax Rate | After-tax Yield | Real Yield | $10K Annual Income |
|---|---|---|---|---|
| 🇺🇸 Roth IRA / 401k | 0% | 25.71% | 22.91% | $2,571 / yr |
| 🇺🇸 US Taxable (15%) ✓ | 15% | 21.85% | 19.05% | $2,185 / yr |
| 🇺🇸 US Taxable (20%) | 20% | 20.57% | 17.77% | $2,057 / yr |
| 🇬🇧 UK ISA | 0% | 25.71% | 22.91% | $2,571 / yr |
| 🇬🇧 UK Taxable | 8.75% | 23.46% | 20.66% | $2,346 / yr |
| 🇨🇦 TFSA | 0% | 25.71% | 22.91% | $2,571 / yr |
| 🇨🇦 CA Taxable | 25% | 19.28% | 16.48% | $1,928 / yr |
| 🇦🇺 Super (pension) | 15% | 21.85% | 19.05% | $2,185 / yr |
| 🇦🇺 AU Taxable | 30% | 18.00% | 15.20% | $1,800 / yr |
| 🇩🇪 DE Taxable | 26.375% | 18.93% | 16.13% | $1,893 / yr |
| 🇫🇷 FR Taxable | 30% | 18.00% | 15.20% | $1,800 / yr |
Real yield = after-tax yield minus US CPI of 2.8%. 12-month CPI (US BLS via FMP economic-indicators). Click any row to select. US withholding tax (30%, reducible by treaty) applies to non-US residents holding US stocks in taxable accounts.
🎯 XGN Income Goal & Break-Even
12-month CPI (US BLS via FMP economic-indicators).
Based on current dividend of $2.00/share/yr · 🇺🇸 US Taxable (15%) · static projection (no growth assumed).
📅 XGN Dividend Payment Schedule
XGN pays quarterly — 4 times per year. Next ex-div: TBD.
📊 XGN vs Healthcare Benchmarks
How XGN compares to typical Healthcare averages.
Benchmarks: S&P 500 sector averages (2024–2026). Sources: Morningstar, Bloomberg, NAREIT. 5Y CAGR for XGN sourced from FMP /financial-growth endpoint — real data, not estimates.
🏛️ XGN Insider Activity
When executives buy their own stock, it's a signal they believe in the dividend's sustainability.
| Insider | Title | Type | Date | Shares | Price | Total Value |
|---|---|---|---|---|---|---|
| A-Award | 2026-09-01 | 1,571 | $3.02 | $4.7K | ||
| Sale | 2026-09-01 | 20,614 | $7.22 | $148.8K | ||
| A-Award | 2026-06-09 | 37,500 | $4.31 | $161.6K | ||
| A-Award | 2026-06-09 | 37,500 | $4.31 | $161.6K | ||
| A-Award | 2026-06-09 | 37,500 | $4.31 | $161.6K | ||
| A-Award | 2026-06-09 | 37,500 | $4.31 | $161.6K | ||
| A-Award | 2026-06-09 | 37,500 | $4.31 | $161.6K | ||
| A-Award | 2026-06-09 | 37,500 | $4.31 | $161.6K | ||
| A-Award | 2026-02-27 | 1,511 | $3.08 | $4.6K | ||
| A-Award | 2026-03-12 | 75,000 | $3.16 | $237.0K |
Insider transactions sourced from SEC Form 4 filings via Financial Modeling Prep. See disclaimer.
Analyst Price Target
Wall Street consensusAnalyst consensus price target via FMP. Not a guarantee of future performance. Past analyst accuracy varies.
Financial Health Scores
Altman Z-Score predicts bankruptcy risk. Piotroski F-Score measures financial strength across 9 criteria. High scores → lower dividend cut risk. Data via FMP financial statements.
Dividend yields, payout ratios, and financial metrics are sourced from Financial Modeling Prep (FMP) and cross-referenced with SEC EDGAR filings. Data is cached and updated every 24 hours via our nightly refresh. DRIP projections are forward-looking estimates, not guarantees.
Educational purposes only. Not financial advice. DividendFlow is not a registered investment advisor. Projections generated by the XGN dividend calculator are estimates based on historical data and user inputs. Actual future returns, stock prices, and dividend payments will vary. Dividends can be cut or suspended at any time. All investments carry risk, including the loss of principal. Please consult a qualified financial professional before making any investment decisions. Full disclaimer →
Exagen Inc. (XGN) is currently trading at $7.78, 60% below its 52-week high. The current dividend yield is 25.71% based on an annual payout of $2.00 per share.
XGN (Exagen Inc.) — 25.71% Dividend Yield Analysis
Exagen Inc. (XGN) is a healthcare stock currently trading at $7.78 with a dividend yield of 25.71%. The company pays an annual dividend of $2.00 per share. The payout ratio of 50% suggests the dividend is well-covered by earnings.
- Above-average yield (25.71%) may signal elevated risk — verify sustainability.
Auto-generated from live market data. For educational purposes only — not financial advice.